Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | glycogen phosphorylase, putative | 0.1353 | 1 | 0.5 |
Echinococcus multilocularis | Glycosyl transferase, family 35 | 0.1353 | 1 | 0.5 |
Echinococcus granulosus | glycogen phosphorylase | 0.1353 | 1 | 0.5 |
Trichomonas vaginalis | glycogen phosphorylase, putative | 0.1353 | 1 | 0.5 |
Chlamydia trachomatis | glycogen phosphorylase | 0.1353 | 1 | 0.5 |
Echinococcus multilocularis | glycogen phosphorylase | 0.1353 | 1 | 0.5 |
Echinococcus granulosus | glycogen phosphorylase | 0.1353 | 1 | 0.5 |
Mycobacterium ulcerans | cytochrome P450 51B1 Cyp51B1 | 0.1059 | 0 | 0.5 |
Loa Loa (eye worm) | glycogen phosphorylase | 0.1353 | 1 | 0.5 |
Entamoeba histolytica | glycogen phosphorylase, putative | 0.1353 | 1 | 0.5 |
Schistosoma mansoni | glycogen phosphorylase | 0.1353 | 1 | 0.5 |
Entamoeba histolytica | glycogen phosphorylase, putative | 0.1353 | 1 | 0.5 |
Mycobacterium tuberculosis | Cytochrome P450 51 Cyp51 (CYPL1) (P450-L1A1) (sterol 14-alpha demethylase) (lanosterol 14-alpha demethylase) (P450-14DM) | 0.1059 | 0 | 0.5 |
Leishmania major | lanosterol 14-alpha-demethylase, putative | 0.1059 | 0 | 0.5 |
Trypanosoma brucei | Lanosterol 14-alpha demethylase | 0.1059 | 0 | 0.5 |
Echinococcus granulosus | Glycosyl transferase family 35 | 0.1353 | 1 | 0.5 |
Onchocerca volvulus | Glycogen phosphorylase homolog | 0.1353 | 1 | 0.5 |
Schistosoma mansoni | glycogen phosphorylase | 0.1353 | 1 | 0.5 |
Giardia lamblia | Glycogen phosphorylase | 0.1353 | 1 | 0.5 |
Echinococcus multilocularis | glycogen phosphorylase | 0.1353 | 1 | 0.5 |
Trypanosoma cruzi | Lanosterol 14-alpha demethylase | 0.1059 | 0 | 0.5 |
Trypanosoma cruzi | Lanosterol 14-alpha demethylase | 0.1059 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
LD50 (ADMET) | = 27 mg kg-1 | Acute toxicity in iv dosed mouse | ChEMBL. | 17752 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.